Updates are available Correction dated 2022-09-07

Article History

Received: 28 February 2022

Accepted: 16 June 2022

First Online: 6 July 2022

Change Date: 7 September 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s12873-022-00701-w

Declarations

:

: The protocols of this study were examined and approved by the institutional review board of Shizuoka General Hospital (Shizuoka, Japan; SGHIRB#2020021). All methods were carried out in accordance with the relevant guidelines and regulations. Given the nature of the study (observational study with routinely collected claim data), a formal waiver of individual informed consent and approval of the study protocol was granted by the institutional review board of Shizuoka General Hospital.

: Dr. Yamamoto has received consultation fees from Mitsubishi Tanabe Pharma, speaker fees from Chugai Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd., and payment for a manuscript from Astellas Pharma Inc. Dr. Kumamaru has received consultation fees from Mitsubishi Tanabe Pharma and speaker fees from Pfizer Japan Inc. and Johnson & Johnson K.K. Dr. Miyata has received a research grant from AstraZeneca K.K. for an independent research project through the PeoPLe Consortium at Keio University. Drs. Endo, Yamamoto, Kumamaru, Ichihara, and Miyata are affiliated with the Department of Healthcare Quality Assessment at The University of Tokyo. This department is a social collaboration department supported by the National Clinical Database, Johnson & Johnson K.K., and Nipro Corporation. The other authors report no conflicts of interest directly relevant to the content of this article.